// App-Quantinova.ai

: Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Researchers

Presenter

  • Lorenzo Falchi

Principal Investigators

  • Marcel Nijland

  • Sirpa Leppa

  • Martin Hutchings

  • Harald Holte

  • Reid W Merryman

  • Pieternella Lugtenburg

  • Sven De Vos

  • Chan Y. Cheah

  • Jacob Haaber Christensen

  • Luca Arcaini

  • Kristina Drott

  • Mats Hellstrom

  • Lori A. Leslie

  • Umberto Vitolo

  • Ali Rana

  • Aqeel Abbas

  • Liwei Wang

  • Minh Dinh

  • David Belada

Medical Centers

  • Hackensack University Medical Center, Hackensack, NJ

  • Department of Molecular Medicine, University of Pavia, Pavia, Italy

  • Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA

  • Oslo University Hospital, Oslo, Norway

  • Hospital Universitari Vall D'Hebron, Barcelona, Spain

  • Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Department of Hematology, On behalf of the HOVON lymphoma working group, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands

  • Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark

  • th Department of Internal Medicine - Hematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic

  • Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

  • Uppsala University Hospital, Uppsala, Sweden

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

  • KG. Jebsen Centre for B cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway

  • Department of Hematology, University Medical Center Groningen and University of Groningen, Groningen, Netherlands

  • Sir Charles Gairdner Hospital, Nedlands, Australia

  • Helsinki University Hospital Cancer Center, Helsinki, Finland

  • Skane University Hospital, Lund, Sweden

  • Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy

  • Odense University Hospital, Odense, Denmark

Locations

  • United States

  • Australia

  • Sweden

  • Italy

  • Finland

  • Netherlands

  • Denmark

  • Norway

  • Czech Republic

  • Spain

Companies

  • AbbVie Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • B-lymphocyte antigen CD20

  • Twist-related protein 1

Drug/Treatment

  • Lenalidomide

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved